atc_code|tarpsy_only|compound_de|compound_fr|additions|constraints_de|constraints_fr|application|unit|since A07AA12|F|Fidaxomicin|Fidaxomicine||||O|mg|2015 B01AB02|F|Antithrombin III|Antithrombin III||||IV|U|2010 B01AC11|F|Iloprost|Iloprost||||Inhal, IV|mcg|2010 B01AC21|F|Treprostinil|Treprostinil||||IV, SC|mg|2016 B01AX01|F|Defibrotid|Defibrotid||||O, IV, IM|mg|2017 B02BB01|F|Fibrinogen, human|Fibrinogène||||IV|g|2010 B02BD01|F|Blutgerinnungsfaktoren IX, II, VII und X in Kombination|Facteurs de coagulation IX, II, VII et X en association||||IV|U|2010 B02BD02|F|Blutgerinnungsfaktor VIII|Facteur de coagulation VIII |Rec, Plas|||IV|U|2010 B02BD03|F|Faktor-VIII-Inhibitor-bypass-Aktivität|Facteur VIII Inhibitor Bypassing Activity||||IV|U|2010 B02BD04|F|Blutgerinnungsfaktor IX|Facteur de coagulation IX ||||IV|U|2010 B02BD05|F|Blutgerinnungsfaktor VII|Facteur de coagulation VII||||IV|U|2010 B02BD06|F|Von Willebrand-Faktor und Blutgerinnungsfaktor VIII in Kombination|Facteur von Willebrand avec facteur de coagulation VIII en association||||IV|U|2010 B02BD07|F|Blutgerinnungsfaktor XIII|Facteur de coagulation XIII ||||IV|U|2010 B02BD08|F|Eptacog alfa (aktiviert)|Eptacog alfa activé||||IV|mg|2010 B02BD09|F|Nonacog alfa|Nonacog alfa||||IV|U|2010 B02BD10|F|Von Willebrand-Faktor|Facteur Von-Willebrand||||IV|U|2016 B02BD14|F|Susoctocog alfa|Susoctocog alfa||||IV|U|2017 B02BX04|F|Romiplostim|Romiplostim||||SC|mcg|2012 B06AC01|F|C1-Inhibitor, aus Plasma gewonnen|Inhibiteur C1, dérivé du plasma||||IV|U|2013 C01CX08|F|Levosimendan|Lévosimendan||||IV|mg|2012 C02KX01|F|Bosentan|Bosentan||||O|mg|2010 C02KX02|F|Ambrisentan|Ambrisentan||||O|mg|2012 C02KX04|F|Macitentan|Macitentan||||O|mg|2017 C02KX05|F|Riociguat|Riociguat||||O|mg|2017 H01BA04|F|Terlipressin|Terlipressine||||IV|mg|2010 J01XX08|F|Linezolid|Linézolide||||O, IV|mg|2012 J02AA01|F|Amphotericin B|Amphotéricine B||liposomal IV|forme liposomale i.v. |IV|mg|2010 J02AC03|F|Voriconazol|Voriconazole|Susp, Tab|||O, IV|mg|2010 J02AC04|F|Posaconazol|Posaconazole|Susp, Tab|||O, IV|mg|2010 J02AX01|F|Flucytosin|Flucytosine||||IV|mg|2016 J02AX04|F|Caspofungin|Caspofungine||||IV|mg|2010 J02AX05|F|Micafungin|Micafungine||||IV|mg|2012 J02AX06|F|Anidulafungin|Anidulafungine||||IV|mg|2010 J05AD01|F|Foscarnet|Foscarnet||||IV|mg|2010 J05AE14|F|Simeprevir|Siméprévir||||O|mg|2016 J05AX14|F|Daclatasvir|Daclatasvir||||O|mg|2017 J05AX15|F|Sofosbuvir|Sofosbuvir||||O|mg|2016 J05AX16|F|Dasabuvir|Dasabuvir ||||O|mg|2016 J05AX65|F|Sofosbuvir und Ledipasvir|Sofosbuvir et lédipasvir|CHV|||O|UD|2016 J05AX67|F|Ombitasvir, Paritaprevir und Ritonavir|Ombitasvir, paritaprevir et ritonavir |CVK|||O|UD|2016 J05AX68|F|Elbasvir und Grazoprevir|Elbasvir et grazoprévir|CZR|||O|UD|2017 J06BA02|F|Immunglobuline, normal human, zur intravasalen Anwendung|Immunoglobulines humaines non spécifiques, application intravasculaire||||IV|g|2010 J06BB04|F|Hepatitis-B-Immunglobulin|Immunoglobuline anti-hépatite B||||IM, IV, SC|U|2013 J06BB09|F|Cytomegalievirus-Immunglobulin|Immunoglobuline anti-cytomégalique||||IV|U|2010 J06BB16|F|Palivizumab|Palivizumab||||IM|mg|2010 L01AB01|F|Busulfan|Busulfan||||O, IV|mg|2010 L01AD01|F|Carmustin|Carmustine||Implantierbarer Medikamententräger|chambre implantable|IT|mg|2010 L01BA04|F|Pemetrexed|Pemetrexed||||IV|mg|2010 L01BA05|F|Pralatrexat|Pralatrexate||||IV|mg|2015 L01BB04|F|Cladribin|Cladribine||||IV, SC|mg|2010 L01BB06|F|Clofarabin|Clofarabine||||IV|mg|2010 L01BB07|F|Nelarabin|Nélarabine||||IV|mg|2010 L01BC07|F|Azacitidin|Azacitidine||||IV, SC|mg|2012 L01BC08|F|Decitabin|Décitabine||||IV|mg|2016 L01CX01|F|Trabectedin|Trabectédine||||IV|mg|2013 L01XC02|F|Rituximab|Rituximab||||IV, SC|mg|2010 L01XC03|F|Trastuzumab|Trastuzumab||||IV, SC|mg|2010 L01XC06|F|Cetuximab|Cétuximab||||IV|mg|2010 L01XC07|F|Bevacizumab|Bévacizumab||||IV|mg|2010 L01XC08|F|Panitumumab|Panitumumab||||IV|mg|2012 L01XC10|F|Ofatumumab|Ofatumumab ||||IV|mg|2014 L01XC11|F|Ipilimumab|Ipilimumab||||IV|mg|2017 L01XC12|F|Brentuximab vedotin|Brentuximab védotine||||IV|mg|2014 L01XC13|F|Pertuzumab|Pertuzumab||||IV|mg|2014 L01XC14|F|Trastuzumab emtansin|Trastuzumab emtansine||||IV|mg|2014 L01XC15|F|Obinutuzumab|Obinutuzumab||||IV|mg|2017 L01XC17|F|Nivolumab|Nivolumab||||IV|mg|2017 L01XC18|F|Pembrolizumab|Pembrolizumab||||IV|mg|2017 L01XC19|F|Blinatumomab|Blinatumomab||||IV|mcg|2017 L01XC23|F|Elotuzumab|Elotuzumab||||IV|mg|2017 L01XC24|F|Daratumumab|Daratumumab||||IV|mg|2017 L01XE02|F|Gefitinib|Géfitinib||||O|mg|2013 L01XE03|F|Erlotinib|Erlotinibe||||O|mg|2013 L01XE04|F|Sunitinib|Sunitinib||||O|mg|2010 L01XE05|F|Sorafenib|Sorafénib||||O|mg|2010 L01XE06|F|Dasatinib|Dasatinib||||O|mg|2010 L01XE08|F|Nilotinib|Nilotinib||||O|mg|2010 L01XE11|F|Pazopanib|Pazopanib||||O|mg|2013 L01XE15|F|Vemurafenib|Vémurafénib||||O|mg|2013 L01XE16|F|Crizotinib|Crizotinib||||O|mg|2015 L01XE17|F|Axitinib|Axitinib||||O|mg|2013 L01XE23|F|Dabrafenib|Dabrafénib||||O|mg|2015 L01XE25|F|Trametinib|Tramétinib||||O|mg|2017 L01XE27|F|Ibrutinib|Ibrutinib||||O|mg|2016 L01XE28|F|Ceritinib|Céritinib||||O|mg|2017 L01XE29|F|Lenvatinib|Lenvatinib||||O|mg|2017 L01XE31|F|Nintedanib|Nintédanib||||O|mg|2017 L01XE38|F|Cobimetinib|Cobimétinib||||O|mg|2017 L01XX01|F|Amsacrin|Amsacrine||||IM, IV|mg|2010 L01XX02|F|Asparaginase|Asparaginase||||IM, IV|U|2010 L01XX24|F|Pegaspargase|Pegaspargase||||IM, IV|U|2013 L01XX27|F|Arsentrioxid|Trioxyde d'arsenic||||IV|mg|2012 L01XX32|F|Bortezomib|Bortézomib||||IV, SC|mg|2010 L01XX42|F|Panobinostat|Panobinostat||||O|mg|2017 L01XX43|F|Vismodegib|Vismodégib||||O|mg|2015 L01XX45|F|Carfilzomib|Carfilzomib||||IV|mg|2016 L01XX46|F|Olaparib|Olaparib||||O|mg|2017 L01XX47|F|Idelalisib|Idélalisib||||O|mg|2016 L02BB04|F|Enzalutamid|Enzalutamide||||O|mg|2017 L02BX03|F|Abirateron|Abiratérone ||||O|mg|2014 L03AA13|F|Pegfilgrastim|Pegfilgrastim||||SC|mg|2010 L03AX16|F|Plerixafor|Plerixafor||||SC|mg|2012 L04AA03|F|Antilymphozytäres Immunglobulin (Pferd)|Immunoglobuline anti-lymphocytes (cheval)||||IV|mg|2010 L04AA04|F|Antithymozytäres Immunglobulin (Kaninchen)|Immunoglobuline anti-thymocytes (lapin)|CTG, CFR, CGR|||IV|mg|2014 L04AA23|F|Natalizumab|Natalizumab||||IV|mg|2010 L04AA24|F|Abatacept|Abatacept||||IV, SC|mg|2010 L04AA25|F|Eculizumab|Eculizumab||||IV|mg|2010 L04AA28|F|Belatacept|Belatacept||||IV|mg|2017 L04AA33|F|Vedolizumab|Védolizumab||||IV|mg|2016 L04AA34|F|Alemtuzumab|Alemtuzumab||Behandlung Multiple Sklerose|pour trait. sclérose en plaques|IV|mg|2010 L04AB01|F|Etanercept|Etanercept||||SC|mg|2010 L04AB02|F|Infliximab|Infliximab||||IV|mg|2010 L04AB04|F|Adalimumab|Adalimumab||||IV, SC|mg|2010 L04AB05|F|Certolizumab pegol|Certolizumab pégol||||IV, SC|mg|2010 L04AB06|F|Golimumab|Golimumab||||IV, SC|mg|2010 L04AC05|F|Ustekinumab|Ustekinumab||||SC|mg|2012 L04AC07|F|Tocilizumab|Tocilizumab||||IV, SC|mg|2010 L04AX04|F|Lenalidomid|Lénalidomide||||O|mg|2010 L04AX05|F|Pirfenidon|Pirfénidone||||O|mg|2017 L04AX06|F|Pomalidomid|Pomalidomide||||O|mg|2016 M05BC01|F|Dibotermin alfa|Dibotermie alfa||||IMPL|mg|2010 M05BX04|F|Denosumab|Denosumab||||SC|mg|2012 N05AH03|T|Olanzapin|Olanzapin|CZY|Depotinjektion|injection dépôt|IM|mg|2017 N05AX08|T|Risperidon|Risperidon|CRC|Depotinjektion|injection dépôt|IM|mg|2017 N05AX12|T|Aripiprazol|Aripiprazol|CAM|Depotinjektion|injection dépôt|IM|mg|2017 N05AX13|T|Paliperidon|Paliperidon|CXE|Depotinjektion|injection dépôt|IM|mg|2017 R07AA02|F|Surfactant|Surfactant||||ET|mg|2010 R07AX02|F|Ivacaftor|Ivacaftor||||O|mg|2017 R07AX30|F|Ivacaftor und Lumacaftor|Ivacaftor et lumacaftor|COK|||O|UD|2017 V03AF07|F|Rasburicase|Rasburicase||||IV|mg|2010 V03AF09|F|Glucarpidase|Glucarpidase||||IV|mg|2017